Rheumatoid arthritis: Guidelines for RA therapy-avoiding hamartia

Nature Reviews Rheumatology

Volumn 6, Issue 9, 2010, Pages 505-506

  Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COMORBIDITY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DOCTOR PATIENT RELATION; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; MEDICAL ERROR; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT PARTICIPATION; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SHORT SURVEY; TREATMENT PLANNING;

ARTHRITIS, RHEUMATOID; HUMANS; MEDICATION ERRORS; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY;

EID: 77956275535     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.138     Document Type: Short Survey

References (10)

1. smolen, J. s. et al. eULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964-975 (2010).
2. Kavanaugh, A. Guidelines in rheumatology: quo vadis. Nat. Rev. Rheumatol. 5, 423-424 (2009).
3. Furst, D. e. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann. Rheum. Dis. 69 (suppl. 1), i2-i29 (2010).
4. saag, K. G. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762-784 (2008).
5. nam, J. L. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the eULAR recommendations for the management of RA. Ann. Rheum. Dis. 69, 976-986 (2010).
6. Knevel, R. et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with diseasemodifying antirheumatic drugs: a systematic literature review informing the eULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69, 987-994 (2010).
7. schoels, M. et al. economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the eULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69, 996-1004 (2010).
8. Gaujoux-viala, C. et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the eULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69, 1004-1009 (2010).
9. Kavanaugh, A. et al. effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum. 61, 1592-1600 (2010).
10. Timbie, J. w., Hayward, R. A. & vijan, s. variation in the net benefit of aggressive cardiovascular risk factor control across the Us population of patients with diabetes mellitus. Arch. Intern. Med. 170, 1037-1044 (2010).